A phase I trial assessing the safety and tolerability of a combination incorporating Ampligen, celecoxib with or without Intron A in patients with early-stage triple negative breast cancer (TNBC)
Latest Information Update: 12 Sep 2019
At a glance
- Drugs Celecoxib (Primary) ; Rintatolimod (Primary) ; Antineoplastics
- Indications Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 12 Sep 2019 New trial record
- 10 Sep 2019 According to an AIM ImmunoTech media release, Roswell Park has received the FDA authorization to proceed with the study.
- 10 Sep 2019 According to an AIM ImmunoTech media release, the principal investigator for this study is Dr. Shipra Gandhi and this study will be conducted at Roswell Park Comprehensive Cancer Center.